Nanobiotix SA

Nanobiotix Sa. Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. Specifically, NanoXray products may overcome the current limitations of standard of care in local therapy. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
  • TickerNANO
  • ISINFR0011341205
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Eric Le Berrigaud

Nanobiotix: End of coverage

Brief Comment - Nanobiotix: (BUY, Fair Value EUR35) End of coverage

Dr Jonas Peciulis

Accumulating data for NBTXR3 and IO combo

Nanobiotix has made progress with NBTXR3 as a standalone agent to enhance radiation therapy and now has clinical data from three cancers demonstrating consistent safety, feasibility and transferability of effect across different indications. Nanobiotix has also released preclinical results demonstrating NBTXR3’s ability to enhance the immunogenicity of various cancers, which is the cornerstone idea behind the immuno-oncology (IO) products. We expect an eventful 2017, with several clinical trials reporting results and a potential CE mark approval in mid-2017 for use in soft tissue sarcoma (STS)...

Outlook: Imminent data from two lead clinical trials

The next 12 months will deliver a number of catalysts for Nanobiotix. Readouts from a Phase I/II study with head and neck (H&N) cancer and a Phase II/III study with soft tissue sarcoma (STS) patients are due any time now. H&N cancer will be the second indication with clinical data for Nanobiotix’s lead product NBTXR3, which may have a de-risking effect on other indications in the pipeline due to the physical property of NBTXR3 to universally enhance the effect of radiotherapy. Our valuation of Nanobiotix is €543m.

Update: Plenty of triggers in 2016

2016 started on a positive note for Nanobiotix, with the IND for lead product NBTXR3 approved in prostate cancer. The company is running trials across six indications, some of which will deliver key data this year. Results from the pilot Phase I/II H&N cancer trial are due in H116, followed by a hallmark event – interim pivotal STS trial data – in mid-2016 and an expected CE mark approval by end 2016. Another two Phase I/II studies for liver cancers are also due to report in H216. Our rNPV increases to €527m.

Flash note: NBTXR3 clinical trial starts in liver indications

Nanobiotix has been granted approval in France to commence pilot clinical development with NBTXR3 for the treatment of liver cancers, allowing the start of a Phase I/II study in line with expected timelines. Liver cancers (including both primary and liver metastases) represent the next indications for NBTXR3, with trials in soft tissue sarcoma (STS), head and neck (H&N) cancer and rectal cancer ongoing. Our valuation is €505m.

1 director bought

A director at Nanobiotix bought 49,733 shares at 16.028EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

NANOBIOTIX sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of NANOBIOTIX (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date September 6, 2019, the closing price was EUR 8.40 and its target price was estimated at EUR 6.61.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Nanobiotix 11 Avril 2019

Selon l’article R225-73-1 du code de commerce, pendant une période ininterrompue commençant au plus tard le 21e jour précédant l'assemblée, les sociétés dont les actions sont admises aux négociations sur un marché réglementé publient sur leur site les documents destinés à être présentés à l'assemblée au regard notamment des dispositions des articles L.225-115 et R225-83. Dans le cas présent, il apparaît que la société, pourtant cotée sur un marché réglementée, n’a pas mis à disposition ces documents et ne respecte donc pas cet article du code de commerce permettant aux actionnaires votant par...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch